Last reviewed · How we verify
Dextromethorphan Oral Solution
Dextromethorphan is a non-opioid cough suppressant that acts as an antagonist at the NMDA receptor and sigma-1 receptor to reduce cough reflex.
Dextromethorphan is a non-opioid cough suppressant that acts as an antagonist at the NMDA receptor and sigma-1 receptor to reduce cough reflex. Used for Cough suppression in upper respiratory tract infections and other conditions causing cough.
At a glance
| Generic name | Dextromethorphan Oral Solution |
|---|---|
| Also known as | Rometor Ratiopharm 2 mg/ml oral solution, Ratiopharm |
| Sponsor | Helsinki University Central Hospital |
| Drug class | Non-opioid antitussive |
| Target | NMDA receptor antagonist; sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Cough suppression |
| Phase | FDA-approved |
Mechanism of action
Dextromethorphan suppresses the cough center in the medulla oblongata through NMDA receptor antagonism and sigma-1 receptor modulation. It is a non-narcotic alternative to codeine-containing cough syrups and does not produce analgesia or significant respiratory depression at therapeutic doses. The drug is rapidly metabolized to dextrorphan, which contributes to its pharmacological effects.
Approved indications
- Cough suppression in upper respiratory tract infections and other conditions causing cough
Common side effects
- Drowsiness
- Dizziness
- Nausea
- Constipation
- Headache
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin (PHASE4)
- Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport (PHASE1)
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir (PHASE1)
- BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) (PHASE1, PHASE2)
- Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates (PHASE1)
- Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study (PHASE4)
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |